drugset / Trial / NCT02838225
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
Timeline
- Start
- 2009-01
- Primary completion
- 2016-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |